Imatinib and methazolamide ameliorate COVID-19-induced metabolic complications via elevating ACE2 enzymatic activity and inhibiting viral entry

Li, ZL; Peng, MX; Chen, P; Liu, CS; Hu, A; Zhang, YX; Peng, JY; Liu, J; Li, YH; Li, WX; Zhu, W; Guan, DX; Zhang, Y; Chen, HY; Li, JZ; Fan, DX; Huang, K; Lin, F; Zhang, ZF; Guo, ZL; Luo, HL; He, X; Zhu, YY; Li, LH; Huang, BD; Cai, WK; Gu, L; Lu, YT; Deng, K; Yan, L; Chen, SF

Li, ZL (通讯作者),Sun Yat Sen Univ, Div Vasc Surg, Affiliated Hosp 1, Guangzhou 510080, Guangdong, Peoples R China.;Li, ZL (通讯作者),Sun Yat Sen Univ, Natl Guangdong Joint Engn Lab Diag & Treatment Va, Affiliated Hosp 1, Guangzhou 510080, Guangdong, Peoples R China.;Deng, K (通讯作者),Sun Yat Sen Univ, Zhongshan Sch Med, Inst Human Virol, Key Lab Trop Dis Control,Minist Educ, Guangzhou 510080, Guangdong, Peoples R China.;Deng, K (通讯作者),Sun Yat Sen Univ, Zhongshan Sch Med, Dept Immunol, Guangzhou 510080, Gu

CELL METABOLISM, 2022; 34 (3): 424

Abstract

Coronavirus disease 2019 (COVID-19) represents a systemic disease that may cause severe metabolic complications in multiple tissues including liver, k......

Full Text Link